Use of bacteriophage for discovery of therapeutically relevant antibodies against infectious diseases
Martina L Jones
+ Author Affiliations
- Author Affiliations
National Biologics Facility
ARC Training Centre for Biopharmaceutical Innovation
Australian Institute for Bioengineering and Nanotechnology
The University of Queensland
St Lucia, Qld 4072, Australia
Tel: +61 7 3346 3178
Email: martina.jones@uq.edu.au
Microbiology Australia 40(1) 33-36 https://doi.org/10.1071/MA19007
Published: 26 February 2019
Abstract
Scientists George P Smith and Gregory Winter were recently awarded half of the 2018 Nobel Prize for Chemistry for developing a technology to display exogenous peptides and proteins on the surface of bacteriophage. ‘Phage display' has revolutionised the development of monoclonal antibodies, allowing fully human-derived antibodies to be isolated from large antibody libraries. It has been used for the discovery of many blockbuster drugs, including Humira (adalimumab), the highest selling drug yearly since 2012, with US$18.4b in sales globally in 20171. Phage display can be used to isolate antibodies to almost any antigen for a wide range of applications including clinical use (for cancer, inflammatory conditions and infectious diseases), diagnostic use or as research tools. The technology is accessible to any laboratory equipped for molecular biology and bacteria culture.
References
[1] Philippidis, A. (2018) The top 15 best-selling drugs of 2017. https://www.genengnews.com/a-lists/the-top-15-best-selling-drugs-of-2017/ (accessed 31 January 2019).[2] Smith, G.P. (1985) Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315–1317.
| Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface.Crossref | GoogleScholarGoogle Scholar | 4001944PubMed |
[3] McCafferty, J. et al . (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554.
| Phage antibodies: filamentous phage displaying antibody variable domains.Crossref | GoogleScholarGoogle Scholar | 2247164PubMed |
[4] Clackson, T. et al . (1991) Making antibody fragments using phage display libraries. Nature 352, 624–628.
| Making antibody fragments using phage display libraries.Crossref | GoogleScholarGoogle Scholar | 1907718PubMed |
[5] Marks, J.D. et al . (1991) By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581–597.
| By-passing immunization. Human antibodies from V-gene libraries displayed on phage.Crossref | GoogleScholarGoogle Scholar | 1748994PubMed |
[6] Russel, M. et al. (2004) Introduction to phage biology and phage display. In Phage Display (Clackson, T. and Lowman, H.B. eds). pp. 1–26. Oxford University Press.
[7] Nissim, A. et al . (1994) Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. EMBO J. 13, 692–698.
| Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents.Crossref | GoogleScholarGoogle Scholar | 7508862PubMed |
[8] Ubah, O. and Palliyil, S. (2017) Monoclonal antibodies and antibody like fragments derived from immunised phage display libraries. Adv. Exp. Med. Biol. 1053, 99–117.
| Monoclonal antibodies and antibody like fragments derived from immunised phage display libraries.Crossref | GoogleScholarGoogle Scholar | 29549637PubMed |
[9] Frenzel, A. et al . (2016) Phage display-derived human antibodies in clinical development and therapy. MAbs 8, 1177–1194.
| Phage display-derived human antibodies in clinical development and therapy.Crossref | GoogleScholarGoogle Scholar | 27416017PubMed |
[10] Kaplon, H. and Reichert, J.M. (2018) Antibodies to watch in 2019. MAbs.
[11] Lefranc, M.P. (2011) IMGT, the International ImMunoGeneTics Information System. Cold Spring Harb. Protoc. 2011, 595–603.
| IMGT, the International ImMunoGeneTics Information System.Crossref | GoogleScholarGoogle Scholar | 21632786PubMed |
[12] Reichert, J.M. (2018) Approved antibodies. https://www.antibodysociety.org/news/approved-antibodies/ (accessed 31 January 2019).
[13] Lefranc, M.P. IMGT/mAb-DB. http://www.imgt.org/mAb-DB/query (accessed 31 January 2019).
[14] Chen, Z. et al . (2017) An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing. MAbs 9, 342–349.
| An elaborate landscape of the human antibody repertoire against enterovirus 71 infection is revealed by phage display screening and deep sequencing.Crossref | GoogleScholarGoogle Scholar | 27929745PubMed |
[15] Maruyama, T. et al . (1999) Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Virol. 73, 6024–6030.
| 10364354PubMed |
[16] Trott, M. et al . (2014) Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody. PLoS One 9, e97478.
| Functional characterization of two scFv-Fc antibodies from an HIV controller selected on soluble HIV-1 Env complexes: a neutralizing V3- and a trimer-specific gp41 antibody.Crossref | GoogleScholarGoogle Scholar | 24828352PubMed |
[17] Duan, T. et al . (2009) Human monoclonal Fab Antibodies against West Nile virus and its neutralizing activity analyzed in vitro and in vivo. J. Antivir. Antiretrovir. 1, 36–42.
| Human monoclonal Fab Antibodies against West Nile virus and its neutralizing activity analyzed in vitro and in vivo.Crossref | GoogleScholarGoogle Scholar | 20505850PubMed |
[18] Kramer, R.A. et al . (2005) The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. Eur. J. Immunol. 35, 2131–2145.
| The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries.Crossref | GoogleScholarGoogle Scholar | 15971273PubMed |
[19] Zhu, Z. et al . (2006) Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J. Virol. 80, 891–899.
| Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.Crossref | GoogleScholarGoogle Scholar | 16378991PubMed |
[20] ANZCTR (2016) ACTRN12615000395538. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=368110 (accessed 6 January 2019).
[21] Broder, C.C. et al . (2013) A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res. 100, 8–13.
| A treatment for and vaccine against the deadly Hendra and Nipah viruses.Crossref | GoogleScholarGoogle Scholar | 23838047PubMed |
[22] Zhang, D. et al . (2013) Generation and characterization of a novel recombinant antibody against LMP1-TES1 of Epstein–Barr virus isolated by phage display. Viruses 5, 1131–1142.
| Generation and characterization of a novel recombinant antibody against LMP1-TES1 of Epstein–Barr virus isolated by phage display.Crossref | GoogleScholarGoogle Scholar | 23609879PubMed |
[23] Jo, G. et al . (2018) Generation and characterization of a neutralizing human monoclonal antibody to hepatitis B virus PreS1 from a phage-displayed human synthetic Fab library. J. Microbiol. Biotechnol. 28, 1376–1383.
| 30301315PubMed |
[24] Wu, Y. et al . (2017) Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg. Microbes Infect. 6, e89.
| Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III.Crossref | GoogleScholarGoogle Scholar | 29018252PubMed |
[25] Rukkawattanakul, T. et al . (2017) Human scFvs that counteract bioactivities of Staphylococcus aureus TSST-1. Toxins (Basel) 9, 50.
| Human scFvs that counteract bioactivities of Staphylococcus aureus TSST-1.Crossref | GoogleScholarGoogle Scholar |
[26] Wang, D. et al . (2017) Preparation and characterization of a human scFv against the Clostridium perfringens type A alpha-toxin. Toxicon 130, 79–86.
| Preparation and characterization of a human scFv against the Clostridium perfringens type A alpha-toxin.Crossref | GoogleScholarGoogle Scholar | 28259756PubMed |
[27] Kuhn, P. et al . (2017) Human Anti-Lipopolysaccharid (LPS) antibodies against Legionella with high species specificity. Hum. Antibodies 26, 29–38.
| Human Anti-Lipopolysaccharid (LPS) antibodies against Legionella with high species specificity.Crossref | GoogleScholarGoogle Scholar | 28582852PubMed |
[28] Nian, S. et al . (2016) Development and identification of fully human scFv-Fcs against Staphylococcus aureus. BMC Immunol. 17, 8.
| Development and identification of fully human scFv-Fcs against Staphylococcus aureus.Crossref | GoogleScholarGoogle Scholar | 27129873PubMed |
[29] Wu, D. et al . (2011) Phage displayed peptides to avian H5N1 virus distinguished the virus from other viruses. PLoS One 6, e23058.
| Phage displayed peptides to avian H5N1 virus distinguished the virus from other viruses.Crossref | GoogleScholarGoogle Scholar | 22216234PubMed |
[30] Liu, H. et al . (2014) Selection and characterization of single-chain recombinant antibodies against infectious haematopoietic necrosis virus from mouse phage display library. J. Virol. Methods 205, 61–67.
| Selection and characterization of single-chain recombinant antibodies against infectious haematopoietic necrosis virus from mouse phage display library.Crossref | GoogleScholarGoogle Scholar | 24747010PubMed |
[31] Frenzel, A. et al . (2017) Designing human antibodies by phage display. Transfus. Med. Hemother. 44, 312–318.
| Designing human antibodies by phage display.Crossref | GoogleScholarGoogle Scholar | 29070976PubMed |
[32] Lebani, K. et al . (2017) Isolation of serotype-specific antibodies against dengue virus non-structural protein 1 using phage display and application in a multiplexed serotyping assay. PLoS One 12, e0180669.
| Isolation of serotype-specific antibodies against dengue virus non-structural protein 1 using phage display and application in a multiplexed serotyping assay.Crossref | GoogleScholarGoogle Scholar | 28683141PubMed |
[33] Leow, C.H. et al . (2014) Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein 2. Malar. J. 13, 277.
| Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein 2.Crossref | GoogleScholarGoogle Scholar | 25037150PubMed |
